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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “does
the addition of ginger decrease migraine pain”.
STUDY DESIGN: A systematic review of three peer-reviewed studies published between the
years of 2011-2018.
DATA SOURCES: Three double-blinded randomized control trials were chosen from the
Cochrane Library and PubMed and selected based on patient oriented outcomes and their
relevance to the clinical questions. The study by Martins et al., (Cephalalgia. 2018; 39(1):68-76.
doi: 10.1177/0333102418776016) compared the addition of ginger vs placebo. The study by
Maghbooli et al., (Phytotherapy Research. 2014;28(3):412–415. doi: 10.1002/ptr.4996.)
compared the addition of ginger vs sumatriptan. The study by Cady et al., (Headache. 2011;
51:1078–1086) compared the addition of ginger/feverfew extract vs placebo.
OUTCOME(S) MEASURED: The outcome measured was the reduction of migraine pain 2
hours (2h) post-treatment using patient oriented and reported pain rating using either a four-point
scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) or a visual analogue scale
(VAS).
RESULTS: There was an overall decrease in migraine pain 2h post-treatment with the addition
of ginger. The study conducted by Martins et al., (Cephalalgia. 2018; 39(1):68-76. doi:
10.1177/0333102418776016) showed the addition of ginger significantly reduced migraine pain
compared to placebo after 2h post-treatment reported using a four-point pain scale (p= 0.04). The
study conducted by Maghbooli et al., (Phytotherapy Research. 2014;28(3):412–415. doi:
10.1002/ptr.4996.) revealed similar efficacy in reducing migraine pain between the ginger and
sumatriptan treatment groups with a reduction of 4.6 units (p<0.0001) and 4.7 units (p<0.0001)
in VAS scores respectively. The study conducted by Cady et al., (Headache. 2011; 51:1078–
1086) had a significant decrease in migraine pain reported using a four-point scale 2h posttreatment with a decrease from 1.41 to 1.17 (p=0.01).
CONCLUSIONS: The evidence presented in this review reveals that the addition of ginger did
significantly decrease migraine pain 2h post-treatment. Ginger extract is an affordable
supplement that is easily accessible. Further research is warranted to evaluate the effects of
ginger on migraine pain as monotherapy and to determine a therapeutic dose.
KEY WORDS: Ginger and migraine
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INTRODUCTION
Migraines are a type of primary headache that typically presents as a severe, throbbing,
unilateral headache lasting 4-72 hours and may be accompanied by nausea and vomiting.
Although not required for diagnosis migraine sufferers may also experience an aura which may
present as aphasia, numbness, paresthesia or visual disturbances such as scotomata or
photophobia.
Migraines are a common condition that effects 1 in 7 adults in the US and are the most
common type of primary headaches that lead emergency department (ED) visits.1,2 In 2010, they
accounted for over 908,000 visits to the ED with an estimated annual cost over $700 million in
ED visits.3 Along with the financial cost, there have been several studies that have shown people
suffering from migraines have reported interference with family and social aspects, finances and
work leading to a decrease in quality of life.4,5,6 Migraine patients may be encountered by
physician assistants in many medical specialties including primary care for symptomatic and
prophylaxis treatment options, neurology to rule out other causes of the neurological symptoms
associated with a migraine aura and in the ED for abortive treatments.
Migraines are thought to arise from neurologic dysfunction where vasoactive compounds
irritate the trigeminal nerve leading to neurological inflammation. The auras are hypothesized to
arise from the cerebral cortex, which manifests as the sensory symptoms that many experience
prior to a migraine onset. They typically are also reoccurring and may have triggers including but
not limited to missed meals, sleep deprivation, dehydration and stress.
Currently, the basis of treatment is avoidance of known triggers, symptomatic and
prophylactic therapy. During an acute attack resting in a dark and quiet room along with simple
analgesics such as non-steroidal anti-inflammatories including acetaminophen, ibuprofen and
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aspirin, may alleviate pain. In more severe instances stronger prescription medication may be
necessary. Ergotamines or triptans may be used for their vasoconstrictive properties, but should
be avoided if there is a history of ischemic stroke, peripheral vascular disease, coronary artery
disease, uncontrolled hypertension and during pregnancy. Ergotamines and triptans should not be
used adjunctively or within 24 hours of each other due to the combined vasoconstrictive effects.
Prophylaxis management includes treating comorbidities and choosing medication based on an
individual basis. These include beta-blockers, antidepressants, antiepileptic drugs, botox and
acupuncture. In the ED morphine, an opioid analgesic, is used as the main abortive therapy.7 Due
to the addictiveness of opioids and the recurrent nature of migraines, it is important to consider
other adjunctive treatment options to quickly address migraine pain in acute settings that can be
taken regularly.
Ginger extract, known for its anti-inflammatory properties, have been used in past studies
to treat migraines. Its active compounds gingeroles and shogaols inhibit cyclooxygenase-2
(COX-2) and 5-lipoxygenase (5-LOX) leading to a decrease in prostaglandins and leukotrienes
respectively.8 Some studies have also reported that ginger has the potential to reduce platelet
aggregation.9 Given its anti-inflammatory properties, this review evaluates the effect of ginger on
migraine pain in three double-blinded randomized control trials.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “does the
addition of ginger decreases migraine pain?” The hypothesis is that the addition of ginger will
reduce migraine pain when added to migraine treatment regimens in acute settings.
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METHODS
Three double-blinded randomized controlled trials (RCT) were reviewed to assess the
efficacy of the addition of ginger on migraine pain, as either adjunct therapy or monotherapy.
This review focused on the general patient population that suffered from migraines. The efficacy
was compared to a placebo group in two of the three studies and sumatriptan in the third study.1012

All studies assessed a patient oriented outcome by measuring pain reduction using a patient

reported four-point pain scale score or visual analogue score (VAS).10-12 This systematic review
focuses specifically on the effects of ginger in decreasing migraine pain 2 hours (2h) posttreatment.
A specific search criteria was used to select these studies. Keywords used during the
search included “ginger” and “migraine”. All three studies were published in peer-review
journals, printed in English and selected from the Cochrane Library or PubMed. Inclusion
criteria included any RCT within the last ten years and exclusion criteria included anything
published before 2008. Statistical analyses in each study used either odds ratio (OR), ANOVA or
student t-tests with p-values to determine statistical significance defined as p <0.05. 10-12 The
demographics, inclusion and exclusion criteria of each study is presented below in Table 1. 10-12

OUTCOMES MEASURED
The studies used patient oriented and self-reported results. Martins et al., evaluated
change in pain intensity using a four-point scale (0= no pain, 1= mild pain, 2= moderate pain,
3=severe pain) at 0.5h, 1h, 1.5h and 2h post-treatment.10 Maghbooli et al., evaluated headache
severity using a VAS at 0.5h, 1h, 1.5h, 2h, and 24h post-treatment.11 Cady et al., measured
headache severity on a four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe
pain) at 1h
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and 2h post-treatment.12 This article will only focus on migraine severity 2h post-treatment.
Table 1. Demographics of included studies for Ginger and Migraine pain
Study

Type

#Pts

Age

Inclusion Criteria

Exclusion criteria

W/D

Intervention

Martins et
al.,
(2018)10

Double
blinded
RCT

60

Ginger:
33.9 +
8.3

18-60 yo, migraine
diagnosed >1 year,
frequency: 1-6
migraines per
month

Non-migraine
headaches,
analgesic use>2x
per week, alcohol
or drug use, other
neurologic
diseases,
anticoagulant use

0

Confirmed migraine
diagnosed without
aura by neurologist,
>18 yo, education
level: high school
diploma or higher,
headache frequency
between 2-10days
per month

History of biliary
calculi or peptic
ulcer diseases,
allergic reaction,
hemorrhagic
diathesis or using
anticoagulants,
history of
ischemic heart
disease,
Prinzmetal
angina, pregnancy
or lactation,
headache after
head trauma
Any medical
condition that
could confound
the results of the
study
(investigator’s
opinion), 15 or
more headaches
per month,
utilizing
medication for
acute migraines
15 or more days
per month over
the last 3 months,
women who were
pregnant or
breastfeeding,
anticoagulant use,
known sensitivity
to any component
of the active study
product

0

Addition of 400mg
ginger extract divided
into two capsules in
addition to 100mg IV
of ketoprofen for acute
migraine attack in the
ED. Compared to
100mg IV of
ketoprofen and
placebo.
One- 250 mg capsule
containing ginger
rhizome powder at the
onset of headache
while keeping up with
previous health
maintenance
therapeutic regimens.
Compared to 50 mg
sumatriptan.

Control:
35.1+
6.2

Maghoobli
et al.,
(2013)11

Double
blinded
RCT

100

Ginger:
35.1+
6.2
Control:
33.9 +
8.3

Cady et
al;,
(2011)12

Double
blinded
RCT

60

Ginger:
35.1+
6.2
Control:
33.9 +
8.3

Age: 12-60 yo, met
International
Headache Society
migraine criteria,
with or without an
aura, history of
migraine >1 yr,
frequency:2-6 per
month in the past 3
months and subjects
reported > 75% of
attacks began with
mild headache and
they could
differentiate
between nonmigraine and
migraine, birth
control for women
of child-bearing
age, stabilized on
current medications
for at least 90 days

1

Addition of sublingual
feverfew/ginger drops
at the onset of
headaches. Participants
were asked to wait 2
hours after the
sublingual feverfew/
ginger drops before
using rescue
medication. Compared
to placebo.
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RESULTS
The study conducted by Martins et al., was a single double blinded, randomized clinical
study that included 60 participants, 8 males and 52 females, from the ED of Vera Cruz hospital
in Brazil.10 The participants were randomly allocated into control and treatment groups in a 1:1
ratio using a randomized sequence software generator. 10 In addition to the 100mg IV of
ketoprofen received by both groups, the experimental group (n=30) received 400mg of ginger
extract as adjunct treatment and the control group (n=30) received an odorless, placebo capsulate
with the same color and format as the experiment.10 There was no noted significant difference
between the groups before the start of the trial. 10 It is noted that the exclusion criteria included a
history of anticoagulants use due to the anti-platelet effects of ginger.9,10 The complete list of
inclusion and exclusion criteria can be found in Table 1. No participants withdrew or were lost to
follow up during this trial. 10
The outcomes in the study evaluated headache severity using self-reported pain ratings on
a four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) 2h after
treatment.10 The study used crude odds ratio (OR) with a 95% confidence interval (CI) to
compare the treatment response of ginger extract vs placebo.10 P values <0.05 were considered
statistically significant. It was observed that the reduction in headache pain from severe/mod to
mild/no pain in participants that received ginger extract at 2h post-treatment as compared to the
placebo was significant (p=0.04) as shown in Table 2.10 There was a higher proportion of
patients that reported being pain free 2h post-treatment with ginger extract vs the placebo (56.7
vs 33.3, p=0.03).10 The OR of 7.25 with a CI of 0.81-64.45 (p=0.07) after 2h can be found in
Table 3.10 The OR of 7.25 suggests that improvement in headache severity is 7.25 times higher
in patients that received ginger as part of their treatment as compared to the placebo indicating a
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strong association. However, the p-value of 0.07 makes this association not statistically
significant.
Table 2. Reduction in migraine intensity reported by four-point scale10
Time
Placebo
Ginger
p-value

2h
0.97 +0.07
0.81 +0.04
0.04

Table 3. Response to treatment of migraine pain with ginger extract vs placebo using OR10
Time
OR
CI 95%
p-value

2h
7.25
0.81-64.45
0.07

The study conducted by Maghbooli et al., was a single double blinded, randomized
clinical study with 100 participants, 71 females and 29 males, enrolled from the Neurology
Clinic of Zanjan Vali-e-Asr Hospital in Iran.11 The participants were randomly assigned to two
coequal groups.11 Both groups received a box containing five capsules of either 50mg
sumatriptan for the control group (n=50) or 250mg powder ginger rhizome for the experimental
group (n=50).11 Participants were kept on their maintenance therapy and were advised to take
one capsule with the onset of their migraine for one-month.11 There was no noted significant
difference between the groups before the start of the trial.11 It is noted that the exclusion criteria
included a history of bleeding diathesis or use of anticoagulants due to the anticoagulant effects
of ginger and ischemic heart disease or Prinzmetal’s angina due to the vasoconstrictive effects of
sumatriptan.11 The complete list of inclusion and exclusion criteria can be found in Table 1. No
participants withdrew or were lost to follow up during this trial.11
The outcomes in the study evaluated the headache severity using self-reported visual
analogue scale (VAS) after 2h of treatment administration.11 Results were analyzed using student
t-tests and two-tailed p-values to assess treatment response, with p<0.05 considered significant.11
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Similar efficacy at 2h post-treatment was observed in sumatriptan and ginger groups, revealing a
unit reduction of 4.7 (p<0.0001) and 4.6 (p<0.0001) on the VAS respectively.11 The continuous
data presented in the study was converted into dichotomous data by defining “improvement” as
patients with a baseline “moderate or severe” headaches that measured “free of headaches” after
2h, and “no improvement” as patients that measured “mild headaches” after 2h. This was done
for both the ginger and sumatriptan groups and can be found in Table 4. The NNH indicates that
for every 34 people that are treated with ginger, one person will have a negative or adverse
effect, making this a small treatment effect. The relative benefit increase (RBI) of 5.27% further
supports this intervention to have a small treatment effect.
Table 4. Efficacy of Ginger in Reducing Migraine Pain
Study
Maghbooli et
al., 11
Cady et al., 12

EER
60.7%

CER
63.9%

RBI
5.27%

ABI
-0.032

NNT
----

NNH
34

57.0%

37.9%

50.4%

0.191

6

----

EER: experimental event rate; CER: control event rate; RBI: relative benefit increase;
ABI: absolute benefit increase; NNT: number needed to treat; NNH: number needed to harm

The study conducted by Cady et al., was a double blinded, randomized clinical study with
60 participants, 14 males and 46 females, conducted at three sites in the USA over a one-month
period. 12 It is noted that one patient withdrew because of pregnancy.12 The participants were
randomly assigned using an online generator to the experimental group (n=45) and placebo
group (n=15) at a ratio of 3:1.12 Both groups were encouraged to administer two units of their
sublingual drops five minutes apart at the onset of mild migraine pain. 12 Another administration
of two units in the same manner was acceptable if the headache pain persisted for one hour. 12
Additional rescue medication, once approved by the case investigator, was allowed if pain
persisted for two hours after the first treatment.12 This study was generalized to children >12
years old, men and non-pregnant women that suffered from migraines.12 It is noted that the

Nguyen, Ginger and migraine pain 8
exclusion criteria included a history of anticoagulants use due to the anticoagulant effects of
ginger.12 The full list of inclusion and exclusion criteria can be found in Table 1.
The outcomes in the study evaluated headache severity using self-reported ratings on a
four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) after 2h of
treatment administration.12 The data was analyzed using a 2-way analysis of variance (ANOVA)
and p-values, with values p<0.05 considered statistically significant.12 It is noted that there was
“modest randomized imbalance and significant difference between the two groups” at the time of
treatment.12 The initial headache severity for the active and placebo group was 1.41 and 1.67
respectively (p=0.01).12 At 2h post-treatment there was a significant decrease in headache
severity in the experiment group (1.41 to 1.17, p=0.01) compared to the placebo (1.67 to 1.71,
p=0.81). 12 Thirty-two percent of subjects reported being pain free 2h post-treatment when taking
sublingual feverfew/ginger as opposed to 16% reported being pain free when taking the placebo
(p=0.02).12
The continuous data presented in the study was converted into dichotomous data by
defining “improvement” as participants who reported having “no pain or mild pain” after 2h, and
“no improvement” as participants that measured “moderate or severe” after 2h. This was done
for both the experiment and placebo group and can be found in Table 4. The NNT of 6 indicated
that for every six people that are treated with feverfew/ginger sublingual drops there will be one
person that will have beneficial migraine pain reduction, making this a small treatment effect.
The RBI of 50.4% further suggests this intervention is a small treatment effect.
Safety and tolerability
Overall, the addition of ginger was well tolerated in all three studies. In the study by
Martins et al., three participant reported dyspepsia after 0.5h post-treatment and only one
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participant still had symptoms after 2h post-treatment.10 The study by Maghbooli et al., also
reported dyspepsia. 11 The study by Cady et al., reported mild adverse effects with the
ginger/feverfew treatment that were similar to the placebo except for oral numbness. These
adverse effects included but are not limited to nausea, oral numbness, vomiting and stomach
cramps. 12
DISCUSSION
The three double-blinded RCTs found that the addition of ginger does decrease migraine
pain, however, the treatment effect is not large. In the study by Martins et al., there was a
significant decrease in migraine pain after 2h post-treatment when comparing the headache
severity between the two groups and more patients reported being pain-free when receiving
ginger after 2h.10 Although the study had an OR of 7.25, this was statistically insignificant
(p=0.07) as discussed above. In the study by Maghbooli et al., there was no significant difference
in the efficacy of ginger when compared to sumatriptan in decreasing migraine pain. 11 The NNH
was calculated to be 34 making this treatment effect small. However, this finding should be
taken into consideration in patients with comorbidities that are contraindications to triptans (i.e.
hypertension or coronary artery disease) making the addition of ginger a possible treatment
option. In the final article conducted by Cady et al., there was a significant decrease in migraine
pain with the addition of ginger, however, the NNT of 6 makes this a small treatment effect. It is
also noted that the ABI of 0.191 indicates that people that add ginger to their treatment regimen
are only 19% more likely to have a decrease in migraine symptoms which further suggests this is
a small treatment effect.12
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Limitations
Other factors to take into consideration includes the quality, accessibility and dosage
amount needed for adjunctive treatment. Ginger extract can be found in many drug and food
stores as a supplement, but it is not approved or regulated by the FDA.13 Although most
insurance drug coverage plans do not cover vitamins and supplements, ginger can be purchased
out of pocket for $9-$16 for 120 capsules of 550mg.14 Unfortunately, there are not enough
studies that have been conducted to determine the therapeutic amount needed to alleviate
migraine pain which makes dosage recommendations difficult.
In the article by Martins et al., one of the limitations was that the treatment plan was to
use the ginger extract or placebo pill adjunctively with ketoprofen, an analgesic which in itself
contributes to the decrease in migraine pain severity. 10 The article by Maghbooli et al., had a
similar limitation, in which their participants were allowed to continue their previous
maintenance therapeutic agents.11 In the article by Cady et al., they used a randomization ratio of
3:1 feverfew/ginger combination to placebo, which makes the study biased towards the
experiment group.12 It is also noted that although the placebo did not include an active analgesic,
feverfew itself has been shown to have anti-inflammatory properties which may have contributed
to the decrease in headache severity reported by participants.15
CONCLUSION
The three articles analyzed in this systematic review suggests that the addition of ginger
does decrease migraine pain, which supports the hypothesis of this systematic review. However,
the treatment effects are small as discussed above. When determining whether or not to consider
ginger as adjuvant treatment for migraine pain it is important to consider all costs and benefits of
treatment and recommendations should be individualized.
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A limitation to this systematic review is that the amount of ginger used in treatment
groups varied between the studies, which could lead to inconsistent treatment effects since there
is currently no standardized recommended treatment dose. There is a limited number of studies
that have been carried out to evaluate the effects of ginger on migraine pain, which also warrants
future studies. More studies are needed using a larger participant population, studies to evaluate
ginger’s effects as monotherapy and studies comparing ginger to a placebo rather than another
medication intervention to fully understand its effects. The anti-inflammatory effects of ginger
are promising and should remain an area of continuous research for the treatment of migraine
pain.
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